@article{RaafatMrochenAl’Sholuietal.2020,
  author    = {Raafat, Dina and Mrochen, Daniel M. and Al'Sholui, Fawaz and Heuser, Elisa and Ryll, Ren{\´e} and Pritchett-Corning, Kathleen R. and Jacob, Jens and Walther, Bernd and Matuschka, Franz-Rainer and Richter, Dania},
  title     = {Molecular epidemiology of methicillin-susceptible and methicillin-resistant Staphylococcus aureus in wild, captive and laboratory rats},
  series = {Toxins},
  volume    = {12},
  journal   = {Toxins},
  number    = {2},
  publisher = {MDPI},
  address   = {Basel},
  issn      = {2072-6651},
  doi       = {10.3390/toxins12020080},
  pages     = {1 -- 22},
  year      = {2020},
  abstract  = {Rats are a reservoir of human- and livestock-associated methicillin-resistant Staphylococcus aureus (MRSA). However, the composition of the natural S. aureus population in wild and laboratory rats is largely unknown. Here, 144 nasal S. aureus isolates from free-living wild rats, captive wild rats and laboratory rats were genotyped and profiled for antibiotic resistances and human-specific virulence genes. The nasal S. aureus carriage rate was higher among wild rats (23.4\%) than laboratory rats (12.3\%). Free-living wild rats were primarily colonized with isolates of clonal complex (CC) 49 and CC130 and maintained these strains even in husbandry. Moreover, upon livestock contact, CC398 isolates were acquired. In contrast, laboratory rats were colonized with many different S. aureus lineages—many of which are commonly found in humans. Five captive wild rats were colonized with CC398-MRSA. Moreover, a single CC30-MRSA and two CC130-MRSA were detected in free-living or captive wild rats. Rat-derived S. aureus isolates rarely harbored the phage-carried immune evasion gene cluster or superantigen genes, suggesting long-term adaptation to their host. Taken together, our study revealed a natural S. aureus population in wild rats, as well as a colonization pressure on wild and laboratory rats by exposure to livestock- and human-associated S. aureus, respectively.},
  language  = {en}
}
@article{GhodsGeorgiouSchmidtetal.2020,
  author    = {Ghods, Mojtaba and Georgiou, Iakovos and Schmidt, Jeremias and Kruppa, Philipp},
  title     = {Disease progression and comorbidities in lipedema patients},
  series = {Dermatologic therapy},
  volume    = {33},
  journal   = {Dermatologic therapy},
  number    = {6},
  publisher = {Wiley-Blackwell},
  address   = {Oxford},
  issn      = {1529-8019},
  doi       = {10.1111/dth.14534},
  pages     = {8},
  year      = {2020},
  abstract  = {Multiple associated comorbidities have been described for lipedema patients. Disease diagnosis still remains challenging in many cases and is frequently delayed. The purpose of this study was to determine the most common comorbidities in lipedema patients and the impact of surgical treatment onto disease progression. A retrospective assessment of disease-related epidemiologic data was performed for patients who underwent liposuction between July 2009 and July 2019 in a specialized clinic for lipedema surgery. All patients received a standardized questionnaire regarding the clinical history and changes of lipedema-associated symptoms and comorbidities after surgery. 106 patients who underwent a total of 298 liposuction procedures were included in this study after returning the questionnaire fully filled-in. Multiple comorbidities were observed in the assessed collective. The prevalence for obesity, hypothyroidism, migraine, and depression were markedly increased in relation to comparable nonlipedema populations. Despite a median body mass index (BMI) of 31.6 kg/m(2) (IQR 26.4-38.8), unexpected low prevalence of diabetes (5\%) and dyslipidemia (7\%) was found. Diagnosis and initiation of guideline-appropriate treatment were delayed by years in many patients. After surgical treatment (medium follow-up 20 months, IQR 11-42), a significant reduction of lipedema-associated symptoms was demonstrated. Lipedema occurs with a diversity of associated comorbidities. Therefore, on the basis of available data, the authors suggest the necessity of a multimodal therapy concept for a comprehensive and holistic treatment. Despite a commonly increased BMI, lipedema patients appear to have an advantageous metabolic risk profile.},
  language  = {en}
}
@article{MatthiasRisslingPieperetal.2020,
  author    = {Matthias, Katja and Rissling, Olesja and Pieper, Dawid Aleksander and Morche, Johannes and Nocon, Marc and Jacobs, Anja and Wegewitz, Uta Elke and Schirm, Jaqueline and Lorenz, Robert C.},
  title     = {The methodological quality of systematic reviews on the treatment of adult major depression needs improvement according to AMSTAR 2},
  series = {Heliyon},
  volume    = {6},
  journal   = {Heliyon},
  number    = {9},
  publisher = {Elsevier},
  address   = {London [u.a.]},
  issn      = {2405-8440},
  doi       = {10.1016/j.heliyon.2020.e04776},
  pages     = {7},
  year      = {2020},
  abstract  = {Background: Several standards have been developed to assess methodological quality of systematic reviews (SR). One widely used tool is the AMSTAR. A recent update -AMSTAR 2 -is a 16 item evaluation tool that enables a detailed assessment of SR that include randomised (RCT) or non-randomised studies (NRS) of healthcare interventions. Methods: A cross-sectional study of SR on pharmacological or psychological interventions in major depression in adults was conducted. SR published during 2012-2017 were sampled from MEDLINE, EMBASE and the Cochrane Database of SR. Methodological quality was assessed using AMSTAR 2. Potential predictive factors associated with quality were examined. Results: In rating overall confidence in the results of 60 SR four reviews were rated "high", two were "moderate", one was "low" and 53 were "critically low". The mean AMSTAR 2 percentage score was 45.3\% (standard deviation 22.6\%) in a wide range from 7.1\% to 93.8\%. Predictors of higher quality were: type of review (higher quality in Cochrane Reviews), SR including only randomized trials and higher journal impact factor. Limitations: AMSTAR 2 is not intended to be used for the generation of a percentage score. Conclusions: According to AMSTAR 2 the overall methodological quality of SR on the treatment of adult major depression needs improvement. Although there is a high need for summarized information in the field of mental health, this work demonstrates the need to critically assess SR before using their findings. Better adherence to established reporting guidelines for SR is needed.},
  language  = {en}
}